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Incubation of 1321N1 human astrocytoma cells with 
carbachol  resulted  in a rapid loss of binding of  [3H] N- 
methylscopolamine ([3H]NMS) to muscarinic cholin- 
ergic  receptors measured at 4 O C  on intact cells; loss of 
muscarinic receptors in lysates from the same cells 
measured with [3H]quinuclidinyl benzilate (r3H]QNB) 
at 37 “C occurred at a slower  rate. Upon removal of 
agonist from the medium, the lost r3H]NMS binding 
sites measured on intact cells recovered  with a tH of 
approximately 20 min, but only to  the  level  to which 
[3H]QNB binding  sites  had been lost; no recovery of 
“lost” r3H]QNB binding  sites  occurred  over  the same 
period. Based on these data  and  the  arguments of Gal- 
per et d. (Galper, J. B., Dziekan, L. C., O’Hara, D. s., 
and Smith, T. W. (1982) J. Biol. Chem. 257,  10344- 
10356) regarding  the  relative  hydrophilicity of r3H] 
NMS uersus r3H]QNB, it is proposed that carbachol 
induces a rapid  sequestration of muscarinic receptors 
that  is followed by a loss of these  receptors  from  the 
cell. These carbachol-induced changes are accom- 
panied by a change  in the membrane  form of the mus- 
carinic  receptor. Although essentially all of the mus- 
carinic  receptors  from  control cells co-purified with 
the plasma membrane  fraction on sucrose  density gra- 
dients, 20-35% of the muscarinic  receptors  from cells 
treated  for 30 min with 100 PM carbachol  migrated  to 
a much lower  sucrose density. This conversion of mus- 
carinic receptors to a “light vesicle” form occurred 
with a tH = 10 min, and reversed  with a tu = 20 min. 
In contrast to previous  results  in this cell line  regarding 
@-adrenergic  receptors  (Harden, T. K., Cotton, C. U., 
Waldo, G. L., Lutton, J. K., and  Perkins, J. P. (1980) 
Science 2 10, 441-443),  agonist  binding  to muscarinic 
receptors  in the light vesicle fraction  obtained  from 
carbachol-treated cells was  still  regulated by GTP. One 
interpretation of these data is that agonists induce an 
internalization of muscarinic  receptors  with  the  reten- 
tion of their functional  interaction  with a guanine  nu- 
cleotide regulatory  protein. 
Many peptide hormone receptors undergo a process of 
agonist-induced receptor clustering and internalization (1). 
In  the case of transferrin (2), asialoglycoprotein (3), and low- 
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density lipoprotein (4) receptors, receptor-mediated endocy- 
tosis is  thought to be involved in the  transport of ligand to 
intracellular sites. The receptor is conserved by recycling back 
to  the cell surface. Although delivery of ligands to intracellular 
sites and receptor recycling clearly are components of the 
ligand-induced internalization process in  the insulin and  ep- 
idermal growth factor receptor systems, receptor degradation 
also is observed (5,6). 
A number of investigators have suggested that catechol- 
amine-induced desensitization of adenylate cyclase also is 
accompanied by ligand-induced internalization of the ,&ad- 
renergic receptor (7-9). Although current technology has  not 
permitted a morphological analysis of this process, the occur- 
rence of 8-adrenergic receptors in a membrane form that is 
not associated with the plasma membrane (7-9) and  that  is 
relatively inaccessible to hydrophilic ligands (10, 11) is con- 
sistent with this idea, As with insulin and epidermal growth 
factor receptors, internalization of ,&adrenergic receptors may 
be a necessary first step for the eventual degradation of 
receptors that occurs during long-term exposure of cells to 
catecholamines (12). 
The 1321N1 human astrocytoma cell line  has proven very 
useful for studies of catecholamine-induced desensitization of 
@-adrenergic receptors (12,13). In addition, these cells express 
a muscarinic cholinergic receptor that when activated results 
in  the breakdown of phosphoinositides (14), the mobilization 
of intracellular Ca2+ (14), and  the activation of a Ca2+/cal- 
modulin-regulated phosphodiesterase (15, 16). We  previously 
have reported (17) that short-term exposure of 1321N1 cells 
to carbachol results  in a reduced capacity of cholinergic ago- 
nists for stimulation of phosphodiesterase; extended exposure 
to agonist results in a loss of muscarinic receptors. The 
potential role of receptor internalization  in these processes 
has not been examined. Indeed, little is known about the 
importance of this process in  the muscarinic receptor system 
and for other hormone receptors that produce their physio- 
logical effects through a breakdown of phosphoinositides. In 
light of the fact that catecholamine-induced alteration  in the 
membrane form of &adrenergic receptors has been studied 
extensively in 1321N1 cells (8,11,18), we have applied similar 
methodology to examine the fate of muscarinic receptors 
during exposure of these cells to cholinergic agonists. 
MATERIALS AND METHODS 
Cell Culture-Human  astrocytoma  cells  (1321N1)  were grown on 
150-mm plastic  culture dishes or six-well plates in  Dulbecco’s  modi- 
fication of Eagle’s medium containing 5% fetal calf serum,  penicillin 
(25 unit/ml), and  streptomycin (25 pg/ml).  Cells  were  subcultured at 
a density of 10,000-15,000 cells/cm2 and maintained in a 37 “c 
humidified incubator in an atmosphere of 92% air and 8% Coz. 
Growth medium was replenished every 3 days,  and  experiments  were 
conducted on postconfluent  cultures 6-8 days  after  subculture. 
Sucrose Density Gradient Experiments-Growth medium was re- 
placed  with 10 ml of Eagle’s  minimal essential medium  buffered  with 
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20 mM Hepes' (Hepes-Eagle's) at  the  start of each experiment. For 
most experiments, cells were incubated with vehicle or a muscarinic 
receptor agonist for 30 min at  37  "C. 
After the completion of experimental treatments,  the medium was 
replaced with 4 "C Hepes-Eagle's containing 0.25 mg/ml of concana- 
valin A (19, 20), and  the dishes were placed on ice for 20 min. Cells 
were hypotonically lysed by rinsing the dishes once with 10 ml of cold 
lysis buffer (1 mM Tris, 2 mM EDTA, pH 7.4)  followed  by a 20-min 
incubation on ice in lysis buffer and subsequent scraping of the 
swollen cells with a rubber policeman. 
For most experiments, pooled lysates (3 ml) from three to four 
150-mm dishes were layered on top of a 9-ml continuous 30-60% 
sucrose density gradient (all gradients were buffered with 10 mM 
Tris, pH 7.4). The gradients were centrifuged in a Beckman SW 40 
rotor at 154,000 X g for 1 h. Twenty 0.6-ml fractions were collected 
from the  top of each gradient at a flow rate of 1.5 ml/min. 
Some experiments (carbachol competition curves) required larger 
amounts of tissue and, thus, larger gradients. Lysates from 25-35 
150-mm dishes were pooled and layered on three 30-ml 30-60% 
continuous sucrose gradients and centrifuged in a Beckman SW 27 
rotor a t  114,000 X g for 1 h. Twenty 2-ml fractions were collected 
from the  top of each gradient a t  a flow rate of 3.0 ml/min. Light 
vesicle fractions and plasma membrane fractions were identified by 
[3H]QNB binding assays (see below), pooled, diluted with 10 mM 
Hepes, pH 7.5, 10 mM EDTA, and centrifuged for 30 min at 170,000 
x g. The  supernatant was discarded, and  the pellet was resuspended 
in  10 mM Hepes, 10 mM EDTA  using a hand-operated Teflon and 
glass homogenizer and centrifuged a second time at  170,000 X g for 
30 min. The final pellet was resuspended in  10 mM Hepes, pH 7.5, 5 
mM MgCb. 
Broken Cell Receptor Assays-Muscarinic receptors were quanti- 
tated with t3H]QNB as previously described (21). Briefly, samples 
were incubated at 37 "C for 60-90 min in  10 mM Hepes, pH 7.5, and 
5 mM MgCI,. The concentration of [3H]QNB was  300 pM for assay 
of gradient  fractions and 30 pM for carbachol competition binding 
experiments. The assay volume  was 1 ml for assay of gradient  frac- 
tions and 10 ml for saturation binding isotherms and competition 
binding assays. Assays were terminated by the addition of 10 ml of 
wash buffer (145 mM NaCl, 10 mM Tris, pH 7.5) to  the reaction tubes 
and filtration over glass fiber filters. The filters were washed with an 
additional  10 mI  of wash buffer and counted in a liquid scintillation 
counter at  an efficiency of 40%. Nonspecific binding was defined as 
the  amount of radioactivity bound in the presence of 1 p M  atropine. 
Cyanopindolol was iodinated and the binding of 1251-cyanopindolol 
to &adrenergic receptors was measured as described elsewhere (22). 
Isoproterenol (100 PM) was used to define nonspecific binding. 
Intact Cell Muscarinic Receptor Assay-Cells grown on six-well 
plates were rinsed twice with 1 ml of 37 "C Hepes-Eagle's to remove 
any previously used drugs. The plates then were placed on ice, and 1 
ml of Hepes-Eagle's containing [3H]NMS (usually 400 PM) was added 
to each well. The plates were incubated for 2.5 h on ice and subse- 
quently washed twice with ice-cold Hepes-Eagle's. The cells were 
solubilized in 1 ml of 1 N NaOH. Aliquots were neutralized with 1 N 
HCl and radioactivity measured in a liquid scintillation counter. 
Nonspecific binding, defined as radioactivity retained in  the presence 
of 1 p M  atropine, was less than 10% of the  total counts. 
Galper et al. (23) have previously reported on the relative hydro- 
philicity of [3H]NMS uersus rH]QNB  and have proposed that t3H] 
NMS can be used to measure "cell-surface" muscarinic receptors 
whereas the lipophilic radioligand [3H]QNB will detect muscarinic 
receptors in a "sequestered" as well as cell surface form. Although 
the data presented below are consistent with this conclusion, the 
assays utilized in  the  current study are somewhat different from those 
employed by Galper et al. (23). First, since the agonist-induced 
changes in muscarinic receptors in 1321N1 cells were rapidly revers- 
ible at 37 "C it was necessary to carry out  intact cell binding assays 
at  4 "C (a temperature a t  which the observed agonist-induced changes 
were not reversible). Second, since binding of [3H]QNB to muscarinic 
ture, intact cell binding assays at  4 "C with I3H]QNB were not 
receptors reaches equilibrium very slowly even at  elevated tempera- 
feasible. In addition, even at elevated  temperatures, there was a high 
level of nonspecific binding of [3H]QNB in intact cell assays. Thus, 
the comparisons in the manuscript are made between intact cell 
' The abbreviations used are: Hepes, 4-(2-hydroxyethyl)-l-pipera- 
zineethanesulfonic acid; [3H]QNB, ~-[benzili~-4,4-~H]quinuclidinyl 
benzilate; ["]NMS, [N-rnethyl-3H]scopolamine chloride. 
assays using [3H]NMS at 4 "C and [3H]QNB binding assays with 
lysates from the same cells a t  37 "C. 
We have previously reported the details of the [3H]QNB binding 
reaction in these cells (15, 17, 21). [3H]NMS bound to muscarinic 
receptors on intact 1321N1 cells at 4 "C with a K d  of 181 & 41 pM (n 
= 3 experiments). This affinity is 3-4-fold less than  the K d  of r3HJ 
NMS obtained in the same cells a t  37 "C (21). Although some varla- 
bility was observed, the number of [3H]NMS binding sites observed 
in intact  1321Nl cells at 4 "C was similar (70-100%) to  the number 
observed with [3H]QNB in 37 "C assays using lysates from the same 
cells.  As  we have previously reported (E),  the density of muscarinic 
receptors (50-200 fmol/mg of protein) varied with the age and density 
of 1321N1 cell cultures. Equilibrium binding of ['HINMS was ob- 
tained within 2 h at  a concentration of  200  pM. 
Materials-The following compounds were purchased from Sigma: 
arecoline hydrobromide, atropine sulfate, carbamyl-8-methylcholine 
chloride (bethanechol), carbamylcholine chloride (carbachol), meth- 
acholine chloride, and oxotremorine sesquifumarate. Concanavalin A 
was purchased from Calbiochem-Behring and ultra-pure sucrose from 
Schwarz/Mann. L3H]QNB (specific activity = 33.4 Ci/mmol) and 
t3H]NMS (specific activity = 84.8 Ci/mmol) were from New England 
Nuclear. NalZ5I was from Amersham. Cyanopindolol was a generous 
gift from Dm. Gunther Engel and Dan Hauser of Sandoz Pharmaceu- 
ticals (Basel, Switzerland). 
RESULTS 
Two types of radioligand binding assays were used for 
assessment of muscarinic receptors in  this study. [3H]QNB 
binding assays were carried out with homogenates at 37 "C 
and  [3H]NMS binding assays were carried out using intact 
ceIls at 4 "C. As discussed under "Materials and Methods" 
and by Galper et al. (23), there  are several reasons to believe 
that  the 13H]QNB binding assay measures "total" receptors 
while the [3H]NMS binding assay measures cell-surface or 
"nonsequestered" receptors. Although there was some varia- 
bility among cultures, the number of muscarinic receptors 
detected on control cultures with each type of radioligand 
binding assay was similar (Fig. 1). Such was not the case 
subsequent to preincubation of 1321N1 cells with carbachol. 
Whereas the number of [3H]NMS binding sites decreased by 
30-40% during a 30-min exposure of cells to 100 PM carbachol, 
Iittle decrease in  the number of [3H]QNB sites occurred (Fig. 
1). In neither case  was there a change in the apparent affinity 
of radioligand, suggesting that  the wash conditions fully re- 
move carbachol from the cultures. 
The time course of loss of [3H]NMS binding sites  is  pre- 
sented in Fig. 2. Receptor density decreased rapidly (tEA = 10 
min) to a new  level from which further decreases occurred at 
a much slower rate. The value for carbachol for induction 
of the loss in binding of  C3H]NMS to intact cells after a 30- 
min incubation with agonist was approximately 10 PM (data 
not shown). The carbachol-induced decrease in  the amount 
of binding of [3H]NMS was rapidly reversible. That is, if 
1321N1 cells were first incubated with 100 PM carbachol for 
45 min, then washed free of agonist and the incubation 
continued in agonist-free medium at 37 ', [3H]NMS binding 
sites reappeared with a tI,% of 15-20 min (Fig. 2). 
We previously have reported (Ref. 17 and Fig. 1) that only 
a small decrease in  the number of binding  sites measured with 
[3H]QNB in homogenates occurs during the first hour of 
incubation of 1321N1 cells with carbachol. Furthermore,  in 
contrast to the rapid recovery of sites measured with [3H] 
NMS in an intact cell binding assay (Fig. Z),  recovery of lost 
[3H]QNB binding sites measured in a homogenate required 
hours (t, FZ 12 h) of incubation of carbachol-pretreated cells 
in agonist-free medium (17). This dichotomy was examined 
further  in  the xperiment depicted in Fig. 3. Cells  were incu- 
bated for the indicated times with 100 PM carbachol. The cells 
then were washed free of agonist and incubation continued in 
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FIG. 1. [3H]NMS and f3H]QNB binding to muscarinic recep- 
tors from carbachol-pretreated 1321N1 cells. Cells were incu- 
bated in  the absence (0) or presence (A) of 100 &M carbachol for 30 
min. The cells then were  washed free of agonist, and two types of 
muscarinic receptor binding assays carried out. In one half of the 
cultures, intact cell binding assays were carried out  at 4 “C using I3H] 
NMS as described under “Materials and Methods” (top panel). The 
other half of the cultures were lysed and [%]$NB binding assays 
carried out at 37 “C as described under “Materials and Methods” 
(bottom  panel). Scatchard  plots are presented with each data point 
representing the average of triplicate determinations. The & and 
B,. values for [’HINMS binding with control cultures were 230 pM 
and 18 fmol/well, respectively, and for carbachol~p~treated cultures 
were 290 pM and 11 fmol/well, respectively. The K d  and B- values 
for [3H]QNB binding with control  cultures were 14 p~ and 17 fmol/ 
well, respectively, and for carbachol-pretreated cultures were 12 pM 
and 16 fmol/well, respectively. The results are representative of those 
from three experiments. 
agonist-free medium. At the indicated times, receptor number 
was assessed in homogenates with [3H]QNB and on intact 
cells  using E3H]NMS at  4 ”C as described under “Materials 
and Methods.” As was  previously  discussed, the loss of 13H] 
NMS binding sites occurred at a faster rate  than did loss of 
~ 3 ~ ~ Q N 3  binding sites. In addition, the changes io receptor 
number measured with these two assays subsequent to re- 
moval of agonist from the incubation medium were very 
different. Whereas the number of [%]NMS binding sites 
recovered to approximately the level of [’HIQNB binding 
sites, there was no increase in the number of E3H]$NB sites 
(if anything, there was  a tendency for a further small decrease 
in the number of [‘H]QM% sites). Thus, during incubation of 
1321N1 cells with carbachol,  muscarinic receptors measured 
in an  intact cell  assay with 13H]NMS decrease and recover 
much faster than those measured with [3H]QNB, and recovery 
of I3H]NMS binding sites occurs  approximately to the level 
of J3H]QNB binding sites that remain after the precincuba- 
tion with agonist. 
We previously demonstrated that incubation of 1321N1 
cells with catecholamine results in a  change in the membrane 
form of &adrenergic receptors (8,11,18). Using similar meth- 
odology, the possibility was examined that changes in rH] 
NMS binding to  intact cells are accomp~ied by changes in 
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FIG. 2. Carbachol-induced  changes in 13H]NMS binding to 
intact 1321Nl astrocytoma cells. Cells were incubated at 3’7 “C 
without agonist (O), with 100 PM carbachol (0) for the indicated 
times, or with 100 p~ carbachol for 45 min prior to washing the 
cultures free of agonist and continuing the incubation in agonist-free 
medium (A). At  the indicated times, the cells were  washed and intact 
cell [%]NMS binding assays were carried out at 4 “C  as described 
under “Materials and Methods.” Each point represents the mean 
value for triplicate plates of cells. The results are representative of 
those observed in four experiments. 
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FIG. 3. Reversal of e ~ b a e h ~ l - i n d u c ~  changes in 13H]NMS 
and (‘HIQNB binding. Cells were incubated with 100 pM carbachol 
for the indicated tinies. The cells then were washed free of agonist, 
and either rH]NMS binding (0) assays (intact cells at 4 “C; see 
“Materials and Methods”) or [’HJQNB binding (A) assays (lysates at 
37 “C; see “Materials and Methods”) were carried out or incubation 
was continued in agonist-free medium prior to  carrying out f3H]NMS 
(0) or 13H]QNB (A) binding assays. The  data are presented as the 
per cent of the specific binding of each radioligand measured in cells 
not incubated with carbachol. The data are the average of two 
experiments carried out with  triplicate dishes. 
the membrane  form of muscarinic  receptors.  Cells were in- 
cubated with 100 PM carbachol for 30 min prior to lysis and 
centrifugation of lysates on sucrose density gradients. As we 
have reported previously (18), essentially all of the muscarinic 
receptors identified with t3N]QNB co-purified with markers 
for the plasma  membrane  (Fig. 4). Subsequent to incubation 
of 1321N1 cells with carbachol for 30 min, there was a 
decrement in the number of receptors appearing in  the plasma 
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FIG. 4. Carbachol-induced  change  in  the  membrane  form of 
muscarinic  cholinergic  receptors. 1321N1 cells were incubated 
with 100 SM carbachol (CARB) for 30 min. The cells then were 
washed free of agonist and  h~otonically l sed, and sucrose density 
gradient centrifugation was performed as described under  “Materials 
and Methods.” [3H]QNB binding assays were carried out on each 
fraction as described under  “Materials and Methods.” The  data  are 
presented as  the amount of r3H]QNB ~~d ~ ~ i ~ c ~ ~ y  per fraction. 
The data are representative of 15 similar experiments. Imet, 8- 
adrenergic receptors were measured in each gradient fraction using 
1251-cyanopindolol (laSI-CYP). The results are representative of those 













FIG. 5. Time course of carbachol-induced change in the 
membrane  form of muscarinic  receptors. Cells were incubated 
for the indicated times  with 100 SM carbachol prior to hypotonic lysis 
and sucrose density gradient centrifugation as described under “Ma- 
terials and Methods.” The data are presented as the amount of 
specific [3HJQNB binding/fraction and  are representative of results 
from three experiments. 
membrane fraction of the gradients and a corresponding 
increase in  the number of receptors appearing at much lighter 
sucrose densities. This carbachol-induced appearance of mus- 
carinic receptors in a “light vesicle” fraction was apparently 
receptor-selective since no carbachol-induced  change in  the 
dist~bution of @-adrenergic receptors (Fig. 4, inset) or HI- 
histamine receptors measured  with t3H]pyrilamine (data  not 
shown)  occurred. 
The time course of the agonist-induced  change in musca- 
rinic receptor distribution on sucrose density gradients also 
was  measured  (Fig. 5).  The tzh (10-15 min) for the agonist- 
induced change in membrane form of muscarinic receptors 
was similar to  that for the loss of [’HINMS binding sites 
measured in intact cell binding assays  (Fig. 2). The maximal 
change in receptor distribution occurred within 45-60 min in 
the presence of 100 PEA carbachol. With extended i n ~ b a t ~ o n ,  
e.g. 90 min in Fig. 5, a decrease in muscarinic  receptor number 
occurred in the light vesicle as well as  the plasma  membrane 
fractions. 
The reversibility of the change in membrane  form also was 
examined. Cells were incubated for 30 min with 100 ~ L M  
carbachol prior to washing the cultures free of agonist and 
continuing the incubation in agonist-free  medium. The cells 
were  lysed after various times of incubation in agonist-free 
medium and sucrose density gradient centrifugation carried 
out as for  Figs. 4 and 5. Following  removal of carbachol, there 
was a t~e-dependent decrease in  the number of receptors 
occurring  in the light vesicle  form and a corresponding in- 
crease in the number of receptors appearing in the plasma 
membrane fraction (data  not shown). The t% of this “recoveryy” 
was 15-20 min. The gradient ~ t r i b u t i o n  of muscarinic re- 
ceptors from cultures that had been incubated for 30 min  with 
carbachol and then incubated in agonist-free medium for 60 
min was indistinguishable from that of control cultures {data 
not shown). 
The concentration dependence for the carbachol-induced 
change in the membrane form of muscarinic receptors is 
presented in Fig. 6. The for carbachool for induction of 
this process was approximately 10 pM which is very similar 
to the of carbachol for stimulation of the breakdown of 
phosphoinositides (5-30 p ~ ;  Refs. 14 and 24) and Ca2+ mo- 
bilization (5-30 p ~ ;  Refs. 14 and 24). Atropine (1 p ~ )  blocked 
the effects of carbachoI on the gradient distribution of mus- 
carinic receptors; no change in the distribution of muscarinic 
receptors occurred  when incubation of 1321N1 cells was with 
atropine (1 p ~ )  alone (data not shown). 
A series of partial agonists (relative to carbachol)  have  been 
identified  based on their capacity to stimulate the breakdown 
of phosphoinositides (14, 24). Cells were incubated with a 
saturating concentration (based  on their capacity to stimulate 
phosphoinositide breakdown) of these agonists for 30 min. 
The number of receptors appearing in the light  vesicle fraction 
was then  quantitated (Table I). There was a very  good corre- 
IBM CARBACHOL 
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FIG. 6. Concentration  dependence of c~bachol-i~duced 
change in the membrane  form of muscarinic  receptors. Cells 
were incubated with the indicated concentrations of carbachol for 30 
min. The cells then were hypotonically lysed, and sucrose density 
gradient centrifugation was carried out as described under “Materials 
and Methods.” Muscarinic receptors in each gradient fraction were 
measured as described under “Materials and Methods.” The data are 
presented as specific [3H]QNB binding/fraction and  are representa- 
tive of results from three experiments. 
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TABLE I 
Induction of light  vesicle  form of muscarinic  receptors by difierent 
ChokIWTgk! UgOfZktS 
1321N1 cells were  incubated  for  30  min  with  the  indicated  agonists 
at a maximally  effective (100 #M with aU agonists  except  bethanechol 
which was present at a concentration of 1000 QM) concentration 
regarding  stimulation  of  phosphoinositide  breakdown (Refs.  14, 24). 
The  cells  were  then  lysed,  and  sucrose  density  gradient centri~ation 
carried  out as described  under  "Materials  and  Methods."  The  fem- 
tomoles  of  receptors  appearing in  the  peak  (fraction 6) fraction  of  the 
light  vesicle  population of receptors  was  quantitated  with I3H]QNB. 
The  data  are  representative  of  results  obtained  in  two  experiments. 
Agonist in 
incubation 
M u s c ~ i ~ c  re eptors in 














lation between the relative efficacy of agonists for stimulation 
of phosphoinositide breakdown and  their effectiveness rela- 
tive to carbachol for induction of the change in membrane 
form of muscarinic receptors. For example, oxotremorine, 
which is approximately 20% as efficacious as carbachol for 
stimulation of phosphoinositide breakdown (14, 24), was ap- 
proximately 30% as effective as carbachol regarding  conver- 
sion of muscarinic receptors to  the light vesicle  form (Table 
I). 
One important observation made concerning the P-adre- 
nergic  receptor of 1321N1 ceIIs  was that @-receptors appearing 
in the light vesicle fraction on sucrose density gradients 
generated from cat~holamine-preincubated cells no longer 
interacted with the stimulatory (regarding adenylate cyclase) 
guanine nucleotide regulatory protein, N, (8). We  have pre- 
sented evidence that  the muscarinic receptors of 1321N1 cells 
interact with a guanine nucleotide  regulatory protein that is 
neither N, or the inhibitory (regarding adenylate cyclase) 
regulatory protein, Ni (25). It was of interest to determine if 
the altered membrane  form of the muscarinic  receptor still 
interacted with this putative guanine kcleotide regulatory 
protein. Cells  were preiacubated with carbachol (100 pM) for 
30 min prior to lysis and centrifugation of the lysates on 
sucrose density gradients. Both the light vesicle and the 
plasma membrane fractions were pooled from several gra- 
dients, and competition curves  for  carbachol were generated 
in the absence and  the presence of GTP. The agonist com- 
petition curves with plasma membrane receptors (Fig. 7, top 
panel) were indistinguishable from those of washed  membrane 
preparations from control cell lysates (data not shown and 
Ref. 25). That is, the addition of GTP markedly shifted the 
agonist competition curve to the right. In contrast to the 
results previously obtained in similar studies with the 8- 
adrenergic receptors of these cells (8), the binding properties 
of muscarinic receptors in the light vesicle fraction from 
carbachol pretreated cells  (Fig. 7, bottom panel) were the same 
as  that of the plasma membrane fraction. That is, carbachol 
inhibited [3H]QNB  binding with high affinity in the absence 
of GTP, and  the carbachol competition curve  was  markedly 
shifted to  the right in assays carried out in the presence of 
100 pM GTP. 
DISCUSSION 
Galper and co-workers (23) have presented evidence that, 
based on their relative hydrophilicities; ['HINMS can be 
l o\ "\ +GTP 
1 , F R A C T  \ a, PUSMA MEMBRANE v) 
.I- 
O n 
Y $? - 1  7 5 3 
I ,I -GTP h 
="L 0 :ACTIO: LIGHT VESICLE 
7 5 3 
FIG. 7. Guanine  nucleotide  regulation of agonist  binding to 
muscarinic  receptors of plasma  membrane  and light vesicle 
fraction. Cells were incubated with 100 QM carbachol for 30 min. 
The cells then were h ~ ~ n i c ~ y  lysed and subjected to sucrose 
density gradient centrifugation as described under "Materials and 
Methods."  The  gradient  fractions  comprising  the  plasma  membrane 
and  light  vesicle  population f muscarinic  receptors  were  both  pooled 
and  subjected to further  centrifugation  as  described  under  "Materials 
and  Methods." The washed  gradient  fractions  were  incubated  with 
[3H]QNB (30 PM) and the indicated concentrations of carbachol. 
Competition curves were generated in the absence (0, A) or in the 
presence (0, A) of 100 QM GTP.  The  data  are  the  average  of tri~l~cate 
assays and are representative of results obtained in seven experi- 
ments. 
utilized in  intact cell  binding  assays to measure  muscarinic 
receptors in a nonsequestered ( c e ~ ~ - s ~ a c e ? )  form, whereas 
['HIQNB can be utilized as a measure of total muscarinic 
receptors. Our preliminary data (see "Materials and Meth- 
ods") as well as  the  data presented in Figs. 1-3 support this 
idea.  However, u n e q ~ v o c ~  onclusions are compromised  by 
the poor  quality of the  data obtained using  [3H]QNB in an 
intact cell  binding  assay, as well as by its very  slow rate of 
association  with the muscarinic  receptor at temperatures that 
are sufficiently low to prevent reversal of agonist-induced 
changes in muscarinic  receptors. 
Assuming that our  ideas  regarding the [3H]NMS and t3H] 
QNB binding assays are correct, then  the following  sequence 
of events can be  proposed. Incubation of 1321N1 cells  with 
carbachol results in rapid conversion of muscarinic receptors 
to a form that is  inaccessible to  the hydrophilic  radioligand 
['HINMS in reduced temperature assays with intact cells. 
Return of these sequestered receptors to the cell  surface is 
rapid upon  removal of agonist from the culture medium. Loss 
of 13H]QNB binding sites during extended  exposure to cholin- 
ergic stimuli occurs at a slower rate than does the loss of 13H] 
NMS binding sites measured  on intact cells  due to  the fact 
that ['HIQNB binding assays in lysed  cells at 37 "C would 
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detect both cell surface receptors and sequestered receptors. 
It can be further proposed that only those receptors that have 
been  modified in a long-lasting way are lost to detection by 
[3H]QNB. The very slow recovery of muscarinic receptors 
measured with ['HIQNB  following transfer of cells to agonist- 
free medium (Ref. 17 and Fig. 3) supports the idea that 
resynthesis of receptors is necessary to recover lost 13H]QNB 
binding sites.  Although none of the  data directly address this 
issue, it is attractive  to consider the sequestered  form of the 
receptor as representative of a step  in the sequence of events 
that results in long-term down-regulation of muscarinic re- 
ceptors. Thus, it can be  hypothesized on the basis of the two 
types of radioligand binding assays that muscarinic receptors 
exist in at least a cell surface form, a sequestered form, and a 
"lost"  form after several hours of incubation of 1321N1  cells 
with carbachol. 
These proposals concerning regulation of muscarinic  recep- 
tors of 1321N1  cells are consistent with those initially made 
by Galper and co-workers  (23).  Based on intact cell binding 
studies with cultured chick  embryo heart cells, these workers 
proposed that 13H]NMS and 13H]QNB recognize different 
forms of the muscarinic  receptor during agonist-induced 
down-re~at ion and that one of these forms represented 
receptors in a sequestered, i.e. internalized, state. These con- 
clusions have  been supported subsequently by studies of mus- 
carinic receptors in several other cell types (26,  27). A major 
difference  between the results obtained with  1321N1  cells and 
those previously reported for chick heart cells should be 
mentioned. That is, whereas lost 13H]NMS binding sites 
rapidly recovered to  the level of [3H]QNB binding sites upon 
transfer of 1321N1 cells to agonist-free medium, the large 
difference in  the number of ~3H]NMS uersuS [3H]QNB bind- 
ing sites in carbachol-pretreated chick heart cells (23) re- 
mained even after incubation in agonist-free  medium  for 60 
min at 37  "C. The reasons for this difference are not clear. 
The interpretation of f3H]NMS and 13H]QNB binding data 
obtained with carbachol-pretreated cells  is supported by re- 
sults obtained using a very different approach. That is, it was 
hypothesized that if carbachol induces  conversion of musca- 
rinic receptors to a sequestered form and if this form at least 
in part represents internalized receptors, then these receptors 
should  no  longer  co-purify with plasma  membrane fractions 
on sucrose density gradients. This, indeed, turned out to be 
the case  when lysates from carbachol-treated cells  were sub- 
jected to sucrose density gradient centr~gation. Although 
there was little or no change in total muscarinic receptors 
measured with f3H]QNB, a portion of these receptors no 
longer  co-purified  with  plasma  membrane fractions after in- 
cubation of 1321N1  cells with carbachol. The fact that  the 
time courses of formation of and recovery  from this altered 
membrane  form were essentially the same as for the agonist- 
induced changes in 13H]NMS binding to intact cells strongly 
argues that these two  very different experimental approaches 
at least in  part measure the same phenomenon.  However, it 
should be pointed out that  the amounts of altered receptors 
measured by these two means were not the same. That is, 
whereas a 30-min incubation of 1321N1  cells  with  carbachol 
resulted in a 35-50% decrease in 13H]NMS  binding to intact 
cells, the amount of receptor converted to a light vesicle form 
measured on sucrose density gradients under the same con- 
ditions was  20-35%. Perhaps this difference  simply is due to 
reversal of the altered membrane form during the long  period 
of time necessary to process samples in the sucrose density 
gradient experiments. Alternatively, incubation with agonists 
may  induce a form of the muscarinic  receptor that is no longer 
accessible to a hydrophilic  radioligand  on the cell surface, but 
that, nonetheless, is still associated with the plasma mem- 
brane. Such a form of the &adrenergic receptor has been 
proposed to be induced by incubation of this cell line (11) or 
other tissues (28)  with  catecholamines. 
Agonist-occupied  muscarinic receptors of 1321N1  cells in- 
teract with a guanine  nucleotide  regulatory protein (24, 25). 
This protein is apparently not Ni based on the insensitivity 
to pertussis toxin of GTP-sensitive high affinity binding of 
agonists (25) and  the lack of effect of pertussis toxin on the 
capacity of muscarinic  receptor agonists to stimulate phos- 
phoinositide breakdown (29), Ca2+  mobilization (29), or phos- 
phodiesterase activity (30). Several lines of evidence from 
1321N1  cells (24) and other tissues (31,  32)  suggest that  this 
yet to be identified guanine  nucleotide  regulatory protein is 
an important component of the coupling  mechanism  involved 
in receptor-mediated stimulation of phosphoinositide break- 
down.  We previously  have  shown that  the uncoupling mech- 
anism involved in catecholamine-induced desensitization of 
the &adrenergic receptorladenylate cyclase  system of 1321N1 
cells  involves a loss of capacity of agonist-occupied &receptors 
to interact with N, (12,  13). Also, &-adrenergic receptors that 
occur in a light vesicle fraction subsequent to incubation of 
1321N1 (8) or other (9) cells  with  catecholamine no longer 
interact with N. Considering these results, it was surprising 
to observe that  the agonist-induced light vesicle  form of the 
muscarinic receptor retained capacity to interact with its 
guanine nucleotide  regulatory protein. It is possible that mus- 
carinic receptors in an agonist-induced  vesicular  form  could 
fuse during the isolation process  with other structures that 
contain the guanine nucleotide  regulatory protein. However, 
this possibility seems highly unlikely. Thus, incubation of 
1321N1  cells with carbachol may result in a co-alteration of 
the membrane  form of both muscarinic receptors and their 
associated guanine nucleotide regulatory protein. Unfortu- 
nately, this putative protein only can be quantified in a very 
indirect way (GTP-sensitive agonist binding), and direct ex- 
amination of this question must await  development of meth- 
odology for identification of the protein. 
Activation of the Ca*+/calmodulin-sensitive phosphodies- 
terase that occurs in response to cholinergic stimuli rapidly 
desensitizes during incubation of  1321N1  cells  with  carbachol 
(17). Based  on the work  of Masters et at. (33), desensitization 
may not occur at  the level of the muscarinic  receptor. They 
have demonstrated that carbachol-stimulated accumulation 
of inositol-l-P04 occurs linearly during a 60-min incubation 
of 1321N1  cells  with  agonist. We do not know at  this time 
what percentage of the inositol-l-PO4 comes  from the second 
messenger, inositol 1,4,5-trisphosphate, and what  percentage 
comes  from the recently  discovered  isomer of unknown  activ- 
ity regarding Ca2+ mobilization, inositol 1,3,4-trisphosphate 
(34). Irrespective of this point, the fact remains that phos- 
phoinositide breakdown is occurring linearly under conditions 
where up to one half of the receptors are apparently in a 
sequestered  form.  One xplanation of these results is that  the 
altered vesicular form of the muscarinic receptor is in an 
environment where both phospholipase C and polyphosphoi- 
nositide substrates are available  for the formation of inositol 
trisphosphates. Thus, assuming  carbachol has sufficient  ac- 
cessibility to  this environment, phosphoinositide  breakdown 
would continue to occur in a cellular  location of receptors 
that is not classically  considered in neurotransmitter action, 
Clearly,  much  more work is  needed addressing all aspects of 
this question to determine its  true significance. 
In summary, we have presented evidence that  the musca- 
rinic receptor that regulates  phosphoinositide  breakdown in 
1321N1  cells  undergoes a change in its membrane  form  upon 
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exposure of these  cells to cholinergic  agonists.  The  properties 
of this change in muscarinic receptors in 1321N1 cells are 
remarkably similar to the catecholam~ne-in~uced changes 
that occur  with the adenylate  cyclase-linked  @-receptor of the 
same cell.  The one  notable  exception to this generalization is 
the observation  that  the  light  vesicle form of the muscarinic 
receptor still interacts  with  a  guanine  nucleotide  regulatory 
protein. This work together  with  that of Masters et al. (33) 
suggests  that phospho~ositide breakdown  in  response to ag- 
onists may  occur in a state of the muscarinic  receptor that is 
not  equivalent  to its normal cell surface  localization. 
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